Affordable Access

Estramustine phosphate (Emcyt) as treatment for metastatic renal carcinoma.

Authors
Type
Published Article
Journal
Urology
0090-4295
Publisher
Elsevier
Publication Date
Volume
17
Issue
4
Pages
344–346
Identifiers
PMID: 7013236
Source
Medline
License
Unknown

Abstract

Sixteen patients completed an adequate trial of estramustine phosphate for the management of metastatic renal cell carcinoma. Although no patient showed a complete or partial response, 9 (56 per cent) had stabilization of disease for a median of 44 weeks. Toxicity was not severe, but intolerance to the drug may limit its widespread use.

Statistics

Seen <100 times